Ucb Biopharma Srl

This study tests a drug called rozanolixizumab in 12 children aged 2 to 17 with moderate to severe generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug is safe and helps control symptoms. Participants receive the drug as a shot un…

This study is testing a drug called zilucoplan in children aged 2 to 17 who have generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see how the drug works in the body, how safe it is, and if it helps control the disease. Only 8 children will ta…

This study looks at the long-term safety of the drug brivaracetam in children and teenagers with absence epilepsy (brief staring spells). About 120 participants who have already taken the drug in earlier studies will continue taking it and be monitored for side effects. The goal …

This study compares two ways of giving the drug bimekizumab to people with active psoriatic arthritis or axial spondyloarthritis: as an IV infusion or a shot under the skin. Researchers want to see if the IV version works just as well as the shot. About 392 adults who are suitabl…

This study tests an inhaled medication called Staccato alprazolam to see if it can stop a prolonged seizure within 90 seconds and prevent it from coming back for at least 2 hours. It is for people aged 12 and older who have predictable, long-lasting seizures. The trial compares t…

This study tests a drug called bimekizumab against a placebo in 300 adults with palmoplantar pustulosis, a skin condition causing painful blisters on hands and feet. The goal is to see if the drug can clear or nearly clear the blisters by 16 weeks. Participants must have moderate…

This study tests a drug called bimekizumab in children aged 2 to 17 with active juvenile arthritis (enthesitis-related arthritis or juvenile psoriatic arthritis). The goal is to measure how the drug moves through the body and check for side effects. About 40 children will take pa…

This study looks at how much of the drug zilucoplan and its breakdown products end up in the breast milk of healthy women who are breastfeeding. About 15 women who are at least 6 weeks postpartum and plan to stop breastfeeding will take daily injections of zilucoplan. Researchers…